TELETRADER News
3/30, 5:37 PM
(Source: TeleTrader)
Sanofi+0.70%
GlaxoSmithKli...+0.77%
EMA begins reviewing Sanofi-GSK COVID-19 vaccine
The European Medicines Agency announced on Wednesday it has started the review of the COVID-19 vaccine jointly developed by French healthcare company Sanofi and its British partner GlaxoSmithKline.
The vaccine known under the name Vidprevtyn, has been determined to be 100% effective against severe COVID-19 and hospitalization, according to the results of the late-stage trials conducted by the two companies.
While the European Union already agreed to buy 300 million doses of the two-shot vaccine for €324 million, GSK also confirmed the companies would request the authorization of the jab in the United States in the upcoming weeks.